RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals announced new data presentations from its clinical trials at the Endocrine Society's Annual Meeting (ENDO 2026). Interim six-month data from a Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) patients demonstrated clinically meaningful improvements in BMI, body composition, hyperphagia, and anxiety. The company also presented long-term efficacy and safety data for setmelanotide in acquired Hypothalamic Obesity (HO) and results for oral bivamelagon in HO, as well as real-world data in Bardet-Biedl Syndrome (BBS).

Rhythm Pharmaceuticals announced positive new data from multiple presentations at ENDO 2026 for its therapies, setmelanotide and bivamelagon. Setmelanotide demonstrated robust, sustained weight loss and improved weight-related outcomes in patients with acquired hypothalamic obesity (HO) and Bardet-Biedl syndrome (BBS). Oral bivamelagon also showed progressive reductions in BMI and hunger in acquired HO patients. These results highlight the potential of MC4R agonism to address hyperphagia and obesity in rare neuroendocrine diseases.

Rhythm Pharmaceuticals announced positive preliminary Phase 2 trial data for setmelanotide in patients with Prader-Willi syndrome (PWS). The 52-week trial, with 17 patients remaining on active therapy, showed clinically meaningful reductions in BMI, fat mass, and improvements in hyperphagia and anxiety measures at the six-month analysis. These results reinforce the rationale for advancing setmelanotide into Phase 3 development for PWS.

Rhythm Pharmaceuticals announced it will host a live conference call and webcast on Saturday, June 13, to discuss interim six-month results from its Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The discussion will feature David Meeker, M.D., Chairman, President and CEO, alongside Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine. Setmelanotide is an MC4R agonist currently approved for other rare neuroendocrine diseases.

Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026). These presentations will feature updated Phase 2 results for setmelanotide in Prader-Willi syndrome, data on bivamelagon for acquired hypothalamic obesity, and long-term efficacy and Phase 3 results for setmelanotide in acquired hypothalamic obesity. Additionally, real-world evidence for setmelanotide in Bardet-Biedl syndrome will be presented, and Dr. Ashley Shoemaker will join the company as a medical director.

Rhythm Pharmaceuticals, Inc. announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. This simplified algorithm, developed by a multidisciplinary group of international experts, is designed to reduce the time to an informed diagnosis of BBS by integrating advances in understanding the disease and genetic testing. The company funded the writing and editorial assistance for the publication, which aims to support earlier diagnosis and timely management for patients.

Rhythm Pharmaceuticals announced that its CEO, David Meeker, and CFO, Hunter Smith, will participate in fireside chats at two upcoming healthcare conferences. Hunter Smith will present at the Jefferies Global Healthcare Conference on June 4, 2026, and David Meeker will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Both presentations will be webcasted live and available for replay on the company's investor relations website.

Rhythm Pharmaceuticals announced new data presentations at The European Congress of Endocrinology for setmelanotide. Real-world data from France showed clinically meaningful BMI reductions of up to 16.9% and improvements in obesity classes in adults with acquired hypothalamic obesity (HO). Phase 3 analyses further demonstrated significant improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO. Additionally, new research highlighted the under-recognition and burden of hyperphagia in Bardet-Biedl syndrome and acquired HO.

Rhythm Pharmaceuticals reported a significant increase in product revenue for the first quarter of 2026, with net product sales jumping 59.3% to $60.1 million. Despite this strong revenue growth, the company's net loss widened to $(55.6) million, up from $(49.5) million in the prior year's quarter. The company maintains a strong liquidity position, with $340.6 million in cash and short-term investments, which management believes is sufficient to fund operations for at least the next 24 months.

Rhythm Pharmaceuticals reported Q1 2026 financial results, with net product revenue of $60.1 million, a 59.4% increase year-over-year. The company announced a strong U.S. launch for IMCIVREE in acquired hypothalamic obesity, receiving over 150 patient start forms in six weeks. European Commission marketing authorization for IMCIVREE in acquired HO was granted, with Japanese regulatory review underway. Despite a net loss of $(56.7) million, the company maintains a strong cash position, expecting to fund operations for at least 24 months.